ClinicalTrials.gg
RecruitingNCT06943274Updated Apr 24, 2025

SWOC Activities on Balance, Gait and Endurance in Children With Autism Spectrum Disorder

An interventional study of Standardized Walking Course Activities and Common Physical Activities in Autism Spectrum Disorder, sponsored by Riphah International University. Recruiting at 1 site in Pakistan. Open to participants aged 8 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Riphah International University · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
8 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Autism Spectrum Disorder by Riphah International University — 13 open to participants now, 13 under way, none of them phase 3. Autism Spectrum Disorder · Riphah International University.

Planned enrollment
3rd of 30
44 · median 31
Started
2025
with 10 others
No phase
30 of 30
13 open now
Primary completion
2025-05
later than 5 of 12 live
Registered
18th of 30
by date

Among the 30 studies in Autism Spectrum Disorder by Riphah International University, this one is the 3rd largest by planned enrollment, is one of 11 that started in 2025, is one of 30 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 18th registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

13 of the 30 studies in Autism Spectrum Disorder by Riphah International University are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.

This study: 8 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Autism Spectrum Disorder by Riphah International University, or all of them as a file.
02

Study summary

Autism Spectrum Disorder (ASD) is a developmental disorder characterized by challenges in social communication, social interaction, repetitive behaviors, and restrictive interests.

Affecting 0.2-2% of children, ASD often includes motor growth retardation, which worsens over time. The disorder is more commonly diagnosed in boys, and its cause is believed to be genetic, with environmental stimuli potentially activating certain genes. This study aims to explore the effects of Standardized Walking Obstacle Course (SWOC) activities on balance, gait, and endurance in children with ASD, seeking to discover novel treatment techniques that could enhance clinical practices and improve motor skills in these children.

This randomized controlled trial will be conducted over 10 months, with data collected from the Lahore Autism Center and PSRD hospital in Lahore, Punjab. The sample will include 44 children with confirmed ASD, aged 8 to 12 years, divided into two groups: one undergoing SWOC activities and the other receiving conventional physiotherapy. Interventions will occur 4 days a week for 30-40 minutes each day. Pre- and post-treatment measurements will be taken using the Pediatric Balance Scale (PBS), the 6-Minute Walk Test (6MWT), and Functional Gait Assessment (FGA).

Data will be analyzed using SPSS version 24, with statistical significance set at P = 0.05.

Read the detailed description

4 weeks treatment plan.

Group A: A randomized controlled trial investigate the effect of a standard walking obstacle course activities on balance, gait and endurance in children with ASD. Activity could include navigating obstacles of varying height and width balancing on beam, stepping over hurdles and walking on different surfaces. 2-3 times for 4 weeks. Balance beam Stepping stones Hurdle Markers Soft Mats Balance activities Gait and Endurance activities

Group B: Either receive no interventions or engages in a different form of physical activities that doesn't focus on balance gait and endurance e.g standard physical education activities like walking, running climbing, jumping along with applied behavioral therapy, speech therapy and customized physical therapy. 2-3 times for 4 weeks.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Autism Spectrum Disorder
  • Balance
  • Standardized Obstacle Course
  • Pediatric balance scale
  • 6-minute walk test
04

Who can participate

Ages eligible
8 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children with confirmed diagnosis of ASD.
  • Age of patients 8 to 12 year.
  • Both male and female.
  • Fall less than 15 times in 30 seconds in Flamingo balance scale test.

Exclusion criteria

Exclusion Criteria:

  • Severe physical impairment.
  • Severe intellectual impairment.
  • Comorbid conditions that could prevent participation.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Group A

    For Group A Standardized Walking Obstacle Course Activities at least 2-3 times a week during a 4-week period.

    Other: Standardized Walking Course Activities

  • Active comparator
    Group B

    For Group B other physical activities at least 2-3 times a week during a 4-week period.

    Other: Common Physical Activities

Interventions

  • OtherStandardized Walking Course Activities

    A randomized controlled trial investigate the effect of a standard walking obstacle course on balance, gait and endurance in children with ASD. Activity could include navigating obstacles of varying height and width balancing on beam, stepping over hurdles and walking on different surfaces. * Balance activities * Gait activities * Endurance activities Start with easier task and end with difficulties. SWOC activities performs 2 to 3 times a week for 4weeks.

  • OtherCommon Physical Activities

    Either receive no interventions or engages in a different form of physical activities that doesn't focus on balance gait and endurance e.g standard physical education activities like walking, running, climbing, jumping along with applied behavioral therapy, speech therapy and customized physical therapy.

06

What researchers measure

Primary outcomes

  1. Pediatric Berg's balance scale for balance assessment

    The Pediatric Balance Scale (PBS), a modification of Berg's Balance Scale, was developed as a balance measure for school-age children with mild to moderate motor impairments. Scoring of PBS is from 0 to 56 and more scores means balance is good and less scores indicated poor balance.intraclass correlation coefficient (ICC) model 3,1 = 0.998 or individual items Kappa Coefficients, k = 0.87 to 1.0; Spearman Rank Correlation Coefficients, r = 0.89 to 1.0 (21). 3.8.2.

    Time frame: Baseline, 4th week

  2. 6-minute walk test

    The 6-minute walk test is a submaximal exercise test used to quantify the functional exercise capacity in clinical populations. Test-retest reliability was undertaken in 52 subjects, and the intraclass correlation coefficient (95% confidence interval) was calculated as 0.94 (0.89-0.96).

    Time frame: Baseline, 4th week

  3. Gait outcome assessment list

    Gait outcome assessment is used to measure and analyze an individual's walking ability, commonly employed in clinical settings for rehabilitation assessment or functional evaluation. It involves scoring parameters like speed, stride length, cadence, and balance during walking tests. The Intraclass Correlation Coefficient (ICC) is 0.89.

    Time frame: Baseline, 4th week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Biffi E, Costantini C, Ceccarelli SB, Cesareo A, Marzocchi GM, Nobile M, Molteni M, Crippa A. Gait Pattern and Motor Performance During Discrete Gait Perturbation in Children With Autism Spectrum Disorders. Front Psychol. 2018 Dec 11;9:2530. doi: 10.3389/fpsyg.2018.02530. eCollection 2018. PubMed 30618953 ↗
  • Rhiel S, Klay A, Keller U, van Hedel HJA, Ammann-Reiffer C. Comparing Walking-Related Everyday Life Tasks of Children with Gait Disorders in a Virtual Reality Setup With a Physical Setup: Cross-Sectional Noninferiority Study. JMIR Serious Games. 2024 Mar 18;12:e49550. doi: 10.2196/49550. PubMed 38498048 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2025, 1 month after the start.

Of 804 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 1 month is below that.

Counting every sponsor, half of 827 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
Apr 24, 2025
StartActual
Apr 15, 2025
Primary completionEst.
May 15, 2025
CompletionEst.
May 31, 2025
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06943274
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Apr 15, 2025
Primary completion
May 15, 2025 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Apr 24, 2025

Study contacts

IMRAN AMJAD, PhD
Contact
imran.amjad@riphah.edu.pk
9233224390125
Muhammad Asif Javed, MS-PT
Contact
a.javed@riphah.edu.pk
923224209422
Kainat Subtain, MS-PPT
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion